MTOR and prostate carcinoma: Only small percentages of blood samples from the prostate cancer patients were positive for CCNH-C5orf30 (5.4% or 8/147), mTOR-TP53BP1 (4.1% or 6/147) and KDM4B-AC011523.2 (1.4% or 2/147).